UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

~~Current~~CURRENT ~~Report~~REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~Report (date of ~~1934~~earliest event reported): September 16, 2025

Date of Report (Date of earliest event reported): August 11, 2025

Insight Molecular Diagnostics Inc.

(Exact name of ~~Registrant~~registrant as specified in its charter)

California	1-37648	27-1041563
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

(615) 255-8880

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities ~~Registered~~registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common ~~stock~~Stock, no par value IMDX The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~August~~September 1116, 2025, the Board of Directors (the “Board”) of Insight Molecular Diagnostics Inc. (~~“we,”~~the “~~us,~~Company”) and ~~“our,”~~the Compensation Committee of the ~~“Company” or~~Board ~~“iMDx”)~~approved ~~issued~~increases ato ~~press~~the ~~release~~annual ~~announcing~~base ~~our~~salaries ~~financial~~of ~~results~~(i) ~~for~~Joshua Riggs, the ~~six~~Company’s ~~months~~President and ~~ended~~Chief ~~June~~Executive 30Officer, ~~2025.~~from A$420,000 ~~copy~~to of$520,000 and (ii) Andrea James, the ~~press~~ ~~release~~Company’s isChief ~~furnished~~Financial asOfficer, ~~Exhibit~~from ~~99.1~~$341,250 to ~~which~~$441,250. inEach ~~its~~of ~~entirety,~~the salary increases is ~~incorporated~~effective ~~herein~~as byof ~~reference~~September 15, 2025.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release dated August 11, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INSIGHT MOLECULAR DIAGNOSTICS INC.
Date: August 11, 2025	By:	/s/ Peter Hong
Date: September 19, 2025	By:	/s/ Peter Hong
	Name:	Peter Hong
		Peter Hong
	Title:	Vice President, General Counsel
		Vice President, General Counsel

Filing Compare · Insight Molecular Diagnostics Inc.